Literature DB >> 10364601

Evaluation of mycology laboratory proficiency testing.

A A Reilly1, I F Salkin, M R McGinnis, S Gromadzki, L Pasarell, M Kemna, N Higgins, M Salfinger.   

Abstract

Changes over the last decade in overt proficiency testing (OPT) regulations have been ostensibly directed at improving laboratory performance on patient samples. However, the overt (unblinded) format of the tests and regulatory penalties associated with incorrect values allow and encourage laboratorians to take extra precautions with OPT analytes. As a result OPT may measure optimal laboratory performance instead of the intended target of typical performance attained during routine patient testing. This study addresses this issue by evaluating medical mycology OPT and comparing its fungal specimen identification error rates to those obtained in a covert (blinded) proficiency testing (CPT) program. Identifications from 188 laboratories participating in the New York State mycology OPT from 1982 to 1994 were compared with the identifications of the same fungi recovered from patient specimens in 1989 and 1994 as part of the routine procedures of 88 of these laboratories. The consistency in the identification of OPT specimens was sufficient to make accurate predictions of OPT error rates. However, while the error rates in OPT and CPT were similar for Candida albicans, significantly higher error rates were found in CPT for Candida tropicalis, Candida glabrata, and other common pathogenic fungi. These differences may, in part, be due to OPT's use of ideal organism representatives cultured under optimum growth conditions. This difference, as well as the organism-dependent error rate differences, reflects the limitations of OPT as a means of assessing the quality of routine laboratory performance in medical mycology.

Entities:  

Mesh:

Year:  1999        PMID: 10364601      PMCID: PMC85142     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Use of proficiency test performance to determine clinical laboratory director qualifications.

Authors:  P J Howanitz
Journal:  Arch Pathol Lab Med       Date:  1988-04       Impact factor: 5.534

2.  Crisis in drug testing. Results of CDC blind study.

Authors:  H J Hansen; S P Caudill; D J Boone
Journal:  JAMA       Date:  1985-04-26       Impact factor: 56.272

3.  Relationship between performance in three of the Centers for Disease Control microbiology proficiency testing programs and the number of actual patient specimens tested by participating laboratories.

Authors:  C W Griffin; M A Mehaffey; E C Cook; S O Blumer; P A Podeszwik
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

4.  Proficiency testing in clinical microbiology: the New York City Program.

Authors:  M E Wilson; Y C Faur; S Schaefler; I Weitzman; M H Weisburd; M Schaeffer
Journal:  Mt Sinai J Med       Date:  1977 Jan-Feb

5.  A summary of the 1972 mycology proficiency testing survey of the College of American Pathologists.

Authors:  C T Dolan
Journal:  Am J Clin Pathol       Date:  1974-06       Impact factor: 2.493

6.  A regional quality control program in microbiology. II. Advantages of simulated clinical specimens.

Authors:  W A Black; S E Dorse
Journal:  Am J Clin Pathol       Date:  1976-08       Impact factor: 2.493

7.  Laboratory evaluation and assistance efforts: mailed, on-site and blind proficiency testing surveys conducted by the Centers for Disease Control.

Authors:  D J Boone; H J Hansen; T L Hearn; D S Lewis; D Dudley
Journal:  Am J Public Health       Date:  1982-12       Impact factor: 9.308

8.  Summary and analysis of the mycology proficiency testing survey results of the College of American Pathologists. 1976-1979.

Authors:  P C Fuchs; C T Dolan
Journal:  Am J Clin Pathol       Date:  1981-10       Impact factor: 2.493

9.  Centers for Disease Control performance evaluation program in bacteriology: 1980 to 1985 review.

Authors:  C W Griffin; E C Cook; M A Mehaffey
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

10.  Mycobacterial testing in clinical laboratories that participate in the College of American Pathologists Mycobacteriology Surveys. Changes in practices based on responses to 1992, 1993, and 1995 questionnaires.

Authors:  G L Woods; T A Long; F G Witebsky
Journal:  Arch Pathol Lab Med       Date:  1996-05       Impact factor: 5.534

View more
  5 in total

1.  Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility.

Authors:  J L Rowen; J M Tate; N Nordoff; L Passarell; M R McGinnis
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  Comparison of API20C with molecular identification of Candida spp isolated from bloodstream infections.

Authors:  J Xu; B C Millar; J E Moore; R McClurg; M J Walker; J Evans; S Hedderwick; R McMullan
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

3.  Proficiency testing program for clinical laboratories performing antifungal susceptibility testing of pathogenic yeast species.

Authors:  Rama Ramani; Vishnu Chaturvedi
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  Isolation of Cryptococcus laurentii from Canada Goose guano in rural upstate New York.

Authors:  Tera Filion; Sarah Kidd; Karen Aguirre
Journal:  Mycopathologia       Date:  2006-11       Impact factor: 2.574

5.  Internal quality assurance in diagnostic microbiology: A simple approach for insightful data.

Authors:  Valentin Scherz; Christian Durussel; Gilbert Greub
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.